CO6420336A2 - Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh - Google Patents
Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodhInfo
- Publication number
- CO6420336A2 CO6420336A2 CO11112334A CO11112334A CO6420336A2 CO 6420336 A2 CO6420336 A2 CO 6420336A2 CO 11112334 A CO11112334 A CO 11112334A CO 11112334 A CO11112334 A CO 11112334A CO 6420336 A2 CO6420336 A2 CO 6420336A2
- Authority
- CO
- Colombia
- Prior art keywords
- salt
- difluorophenyl
- amino
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a la sal de sodio cristalina hidrosoluble de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il)amino}benzoico y a sus solvatos.La invención también proporciona un método de tratamiento de una patología o enfermedad susceptible de ser aliviada por inhibición de dihidroorotato deshidrogenasa, en particular cuando la patología o enfermedad se selecciona de artritis reumatoide, artritis psoriásica, espondilitis anquilosante, esclerosis múltiple, granulomatosis de Wegener, lupus eritematoso sistémico, psoriasis y sarcoidosis, que comprende administrar una cantidad terapéuticamente eficaz de la sal de la invención. La invención proporciona además un método de tratamiento que comprende administrar una cantidad terapéuticamente eficaz de una combinación de la sal de la invención junto con uno o más de otros agentes terapéuticos o administrar una cantidad terapéuticamente eficaz de una composición farmacéutica que comprende dicha combinación.La invención proporciona además procedimientos e intermedios de síntesis descritos aquí, que son útiles para preparar la sal de la invención.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382033A EP2239256A1 (en) | 2009-03-13 | 2009-03-13 | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6420336A2 true CO6420336A2 (es) | 2012-04-16 |
Family
ID=40903239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11112334A CO6420336A2 (es) | 2009-03-13 | 2011-09-01 | Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8501943B2 (es) |
| EP (2) | EP2239256A1 (es) |
| JP (1) | JP2012520250A (es) |
| KR (1) | KR20110125653A (es) |
| CN (1) | CN102348687B (es) |
| AR (1) | AR075736A1 (es) |
| AU (1) | AU2010223526A1 (es) |
| CA (1) | CA2754801A1 (es) |
| CL (1) | CL2011002215A1 (es) |
| CO (1) | CO6420336A2 (es) |
| EA (1) | EA020218B1 (es) |
| EC (1) | ECSP11011383A (es) |
| IL (1) | IL214518A0 (es) |
| MX (1) | MX2011009148A (es) |
| NZ (1) | NZ594492A (es) |
| PE (1) | PE20120114A1 (es) |
| SG (1) | SG173825A1 (es) |
| TW (1) | TW201032811A (es) |
| UA (1) | UA105788C2 (es) |
| UY (1) | UY32466A (es) |
| WO (1) | WO2010102824A2 (es) |
| ZA (1) | ZA201105742B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| EP2444088A1 (en) * | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Amino derivatives for the treatment of proliferative skin disorders |
| US20120195933A1 (en) * | 2011-01-27 | 2012-08-02 | Ralph Stefan | Pharmaceutical compositions comprising tasocitinib |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| EP3193874A4 (en) | 2014-09-17 | 2018-04-25 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| CN114957650B (zh) * | 2022-06-11 | 2024-05-10 | 新疆腾域鸿源农业科技有限公司 | 一种聚天冬氨酸钾的制备方法及其在植物生长促进剂中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE209518T1 (de) | 1995-06-21 | 2001-12-15 | Asta Medica Ag | Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator |
| DE19547648A1 (de) | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
| DE19610955A1 (de) | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| EP1225886A2 (en) | 1999-06-10 | 2002-07-31 | Warner-Lambert Company | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| SI1381356T1 (sl) | 2001-04-05 | 2008-12-31 | Aventis Pharma Inc | Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze |
| WO2002102374A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Amine salt of an integrin receptor antagonist |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
| WO2004056747A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| SE0400234D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New compounds, methods for their preparation and use thereof |
| CN1993125A (zh) | 2004-05-21 | 2007-07-04 | Uab研究基金会 | 涉及嘧啶合成抑制剂的组合物和方法 |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| EP1804782A1 (en) | 2004-10-19 | 2007-07-11 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ES2303758B1 (es) | 2006-02-20 | 2009-08-13 | Laboratorios Almirall S.A. | Nuevos derivados de piridin-3-amina. |
| ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| ATE508108T1 (de) | 2007-02-06 | 2011-05-15 | Chelsea Therapeutics Inc | Neue verbindungen, verfahren zu deren herstellung und deren verwendung |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2210615A1 (en) | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
-
2009
- 2009-03-13 EP EP09382033A patent/EP2239256A1/en not_active Withdrawn
-
2010
- 2010-02-24 UY UY0001032466A patent/UY32466A/es unknown
- 2010-03-08 TW TW099106629A patent/TW201032811A/zh unknown
- 2010-03-11 SG SG2011060837A patent/SG173825A1/en unknown
- 2010-03-11 WO PCT/EP2010/001548 patent/WO2010102824A2/en active Application Filing
- 2010-03-11 MX MX2011009148A patent/MX2011009148A/es active IP Right Grant
- 2010-03-11 CN CN201080011541.4A patent/CN102348687B/zh not_active Expired - Fee Related
- 2010-03-11 AU AU2010223526A patent/AU2010223526A1/en not_active Abandoned
- 2010-03-11 UA UAA201111805A patent/UA105788C2/uk unknown
- 2010-03-11 JP JP2011553358A patent/JP2012520250A/ja active Pending
- 2010-03-11 PE PE2011001598A patent/PE20120114A1/es not_active Application Discontinuation
- 2010-03-11 EP EP10708145A patent/EP2406221A2/en not_active Withdrawn
- 2010-03-11 US US13/256,127 patent/US8501943B2/en not_active Expired - Fee Related
- 2010-03-11 EA EA201101301A patent/EA020218B1/ru not_active IP Right Cessation
- 2010-03-11 NZ NZ594492A patent/NZ594492A/xx not_active IP Right Cessation
- 2010-03-11 AR ARP100100739A patent/AR075736A1/es not_active Application Discontinuation
- 2010-03-11 CA CA2754801A patent/CA2754801A1/en not_active Abandoned
- 2010-03-11 KR KR1020117021316A patent/KR20110125653A/ko not_active Application Discontinuation
-
2011
- 2011-08-04 ZA ZA2011/05742A patent/ZA201105742B/en unknown
- 2011-08-08 IL IL214518A patent/IL214518A0/en unknown
- 2011-09-01 CO CO11112334A patent/CO6420336A2/es not_active Application Discontinuation
- 2011-09-08 CL CL2011002215A patent/CL2011002215A1/es unknown
- 2011-10-07 EC EC2011011383A patent/ECSP11011383A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110125653A (ko) | 2011-11-21 |
| PE20120114A1 (es) | 2012-02-20 |
| CA2754801A1 (en) | 2010-09-16 |
| WO2010102824A2 (en) | 2010-09-16 |
| ECSP11011383A (es) | 2011-11-30 |
| IL214518A0 (en) | 2011-09-27 |
| EP2239256A1 (en) | 2010-10-13 |
| US8501943B2 (en) | 2013-08-06 |
| EA201101301A1 (ru) | 2012-04-30 |
| MX2011009148A (es) | 2011-09-28 |
| NZ594492A (en) | 2013-11-29 |
| CN102348687B (zh) | 2014-04-02 |
| TW201032811A (en) | 2010-09-16 |
| CN102348687A (zh) | 2012-02-08 |
| SG173825A1 (en) | 2011-09-29 |
| ZA201105742B (en) | 2012-04-25 |
| US20120003184A1 (en) | 2012-01-05 |
| EP2406221A2 (en) | 2012-01-18 |
| UY32466A (es) | 2010-09-30 |
| UA105788C2 (uk) | 2014-06-25 |
| WO2010102824A3 (en) | 2010-11-18 |
| AU2010223526A1 (en) | 2011-08-25 |
| CL2011002215A1 (es) | 2012-03-09 |
| EA020218B1 (ru) | 2014-09-30 |
| AR075736A1 (es) | 2011-04-20 |
| JP2012520250A (ja) | 2012-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6420336A2 (es) | Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh | |
| PE20090903A1 (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa | |
| NZ593413A (en) | Combinations comprising methotrexate and dhodh inhibitors | |
| ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| PE20161218A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| NZ589089A (en) | Combinations comprising methotrexate and dhodh inhibitors | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| ECSP13013038A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| UA102336C2 (uk) | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ | |
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| MX2013005533A (es) | Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep. | |
| BR112022010599A2 (pt) | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina | |
| PE20161432A1 (es) | Compuestos y composiciones para inducir condrogenesis | |
| ME01564B (me) | Adicione soli amina koji sadrže hidroksilne i/ ili karboksilne grupe s derivatima aminonikotinske kiseline kao dhodh inhibitorima | |
| PE20090210A1 (es) | Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| NZ594491A (en) | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren | |
| PE20212197A1 (es) | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |